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A B S T R A C T
Based on its capacity to inhibit in vitro HIV-1 replication in T cells and the release of pro-inﬂammatory
cytokines inmonocytes, the prenylated heterodimeric phloroglucinyla-pyrone arzanol was identiﬁed as
the major anti-inﬂammatory and anti-viral constituent from Helichrysum italicum. We have now
investigated the activity of arzanol on the biosynthesis of pro-inﬂammatory eicosanoids, evaluating its
anti-inﬂammatory efﬁcacy in vitro and in vivo. Arzanol inhibited 5-lipoxygenase (EC 7.13.11.34) activity
and related leukotriene formation in neutrophils, as well as the activity of cyclooxygenase (COX)-1 (EC
1.14.99.1) and the formation of COX-2-derived prostaglandin (PG)E2 in vitro (IC50 = 2.3–9mM). Detailed
studies revealed that arzanol primarily inhibits microsomal PGE2 synthase (mPGES)-1 (EC 5.3.99.3,
IC50 = 0.4mM) rather than COX-2. In fact, arzanol could block COX-2/mPGES-1-mediated PGE2
biosynthesis in lipopolysaccharide-stimulated human monocytes and human whole blood, but not
the concomitant COX-2-derived biosynthesis of thromboxane B2 or of 6-keto PGF1a, and the expression of
COX-2 or mPGES-1 protein was not affected. Arzanol potently suppressed the inﬂammatory response of
the carrageenan-induced pleurisy in rats (3.6 mg/kg, i.p.), with signiﬁcantly reduced levels of PGE2 in the
pleural exudates. Taken together, our data show that arzanol potently inhibits the biosynthesis of pro-
inﬂammatory lipidmediators like PGE2 in vitro and in vivo, providing amechanistic rationale for the anti-
inﬂammatory activity of H. italicum, and a rationale for further pre-clinical evaluation of this novel anti-
inﬂammatory lead.
 2010 Elsevier Inc. All rights reserved.
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Inﬂammation is a complex biological response to harmful
stimuli required to remove an offensive agent and to initiate the
healing process. However, chronic inﬂammation can lead to
diseases (e.g., rheumatoid arthritis, atherosclerosis, and autoim-
mune disorders) that still represent unmet clinical needs. The
prostanoids and leukotrienes (LTs) formed from arachidonic acid
(AA) via the cyclooxygenase (COX)-1/2 (EC 1.14.99.1) and 5-
lipoxygenase (5-LO) (EC 7.13.11.34) pathway, respectively, medi-
ate inﬂammatory responses, chronic tissue remodelling, cancer,
asthma, and autoimmune disorders, but also possess homeostatic
functions in the gastrointestinal tract, uterus, brain, kidney,
vasculature, and host defence [1]. In fact, the clinical use of
non-steroidal anti-inﬂammatory drugs (NSAIDs), a class of drugs
that block formation of all prostanoids, is hampered by severe side
effects including gastrointestinal injury, renal irritations, and
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Fig. 1. Radical scavenging activity of arzanol and effects on 5-LO product formation. (A) Chemical structure of arzanol. (B) Radical scavenging activity of arzanol. The assay was
performed as described in the method section. (C) Inhibition of 5-LO activity in a cell-free assay. Semi-puriﬁed human recombinant 5-LO (0.5mg/ml) was pre-incubated with
arzanol or vehicle (veh, DMSO) and 1 mMATP for 10 min on ice, pre-warmed for 30 s at 37 8C, and 5-LO product formationwas started by addition of 2 mMCaCl2 and 20mMAA.
(D) Reversibility of 5-LO inhibition. Semi-puriﬁed human recombinant 5-LO (5mg/ml)was pre-incubatedwith 10mMarzanol or vehicle (veh, DMSO) for 10 min on ice. Then, an
aliquotwas diluted 10-foldwith assay buffer, 1 mMATPwas added, pre-warmed for 30 s at 37 8C, and 5-LO product formationwas started by addition of 2 mMCaCl2 and 20mM
AA.Ascontrols, 0.5mg/ml5-LOwaspre-incubatedwith1or10mMarzanol (or vehicle,DMSO)and5-LOproduct formationwasanalyzedasdescribedabove. (E) Inhibitionof5-LO
activity in a cell-based assay. Neutrophils (5 106 cells/ml) were pre-incubated with the indicated concentrations of arzanol or vehicle (veh, DMSO) for 15 min. 5-LO product
formationwas initiated by addition of 2.5mMA23187 plus 20mMAAor by primingwith LPS (1mg/ml) and addition of 0.3 units Ada, and after 30 min 100 nM fMLPwas added.
The100%valuescorrespondtoanaverageof550 ng/ml5-LOproducts forsemi-puriﬁedenzyme, and335 ng/ml(A23187/AA)or250 pg/ml(LPS/fMLP) for intactcells, respectively.
Data are given as mean + S.E., n = 3–4, *p< 0.05, **p < 0.01 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc tests.
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interfering with eicosanoid biosynthesis require a well-balanced
pharmacological proﬁle to minimize these on-target side effects
[2]. Current anti-inﬂammatory research aims at identifying
compounds that can suppress the massive formation of pro-
inﬂammatory prostaglandin (PG)E2 without affecting homeostatic
PGE2 and PGI2 synthesis, and also inhibit LT formation [3,4]. While
there is no shortage of anti-inﬂammatory natural products that
suppress eicosanoid generation by inhibiting 5-LO and/or COXenzymes [5,6], the activity ofmost of themhas only been evaluated
in terms of expression and/or activity of COX enzymes and 5-LO in
vitro, and high concentrations, unrealistic to translate in a clinical
setting, are often required for activity [5]. Moreover, in many cases
the anti-inﬂammatory activity was not evaluated in vivo, or, if so, it
was not clearly related to an interference with the biosynthesis of
eicosanoids.
Arzanol, a prenylated heterodimeric phloroglucinyl a-pyrone
(Fig. 1A), was identiﬁed as the major anti-inﬂammatory constitu-
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used in folkmedicine to treat inﬂammatory diseases and infections
[7,8]. In fact, extracts of H. italicum have been reported to exhibit
anti-oxidant [7], anti-bacterial [9], anti-fungal [10] and anti-viral
[11] effects. Extensive clinical research on the activity of extracts
from H. italicum to manage inﬂammatory conditions was carried
out by the Italian physician Leonardo Santini in the 40s and 50s.
However, his ﬁndings were published in little known Journals, and,
after his death, were largely overlooked [8]. Arzanol showed anti-
oxidant activity in various systems of lipid peroxidation in vitro,
and protected VERO cells against tert-butyl hydroperoxide (TBH)-
induced oxidative stress [12]. Moreover, arzanol inhibited nuclear
factor kappa beta (NFkB) activation and HIV-1 replication in T cells
(IC50  5mg/ml and 5mM, respectively) as well as the release of
pro-inﬂammatory mediators such as interleukin (IL)-1b, IL-6, IL-8,
tumor necrosis factor (TNF)a, and PGE2 in lipopolysaccharide
(LPS)-stimulated monocytes [8]. Nevertheless, additional molecu-
lar target(s) of arzanolmay exist and its anti-inﬂammatory efﬁcacy
in vivo remains to be investigated. To this aim, we have
investigated the activity of arzanol on the biosynthesis of
prostanoids and LTs, and we have evaluated its anti-inﬂammatory
efﬁcacy in vitro and in vivo. We show that arzanol potently inhibits
the inducible microsomal PGE2 synthase (mPGES)-1 (EC 5.3.99.3),
COX-1, and 5-LO in various test systems with IC50 values between
0.4 and 9mM, and signiﬁcantly reduces the inﬂammatory response
and the PGE2 levels in the carrageenan-induced pleurisy in rats.
These observations validate arzanol as a novel anti-inﬂammatory
chemotype worth further development.
2. Materials and methods
2.1. Reagents
Arzanol was isolated fromH. italicum as described [8], dissolved
in dimethyl sulfoxide (DMSO) and kept in the dark at 20 8C, and
freezing/thawing cycles were kept to a minimum. Arzanol was
found to be stable in neutral medium in polar solvents. Thus, after
96 h at room temperature in DMSO, methanol or acetone, no
degradation could be observed (NMR evidence). For animal
studies, arzanol was dissolved in DMSO and diluted with saline
achieving a ﬁnal DMSO concentration of 4%. The thromboxane
synthase inhibitor CV4151 was a generous gift by Dr. S. Laufer
(University of Tuebingen, Germany). The mPGES-1 inhibitor 2-(2-
chlorophenyl)-1H-phenanthro[9,10-d]-imidazole (MD52) was
synthesized according to [13] and was a generous gift by Dr. M.
Schubert-Zsilavecz (University Frankfurt, Germany). The antibody
against human mPGES-1 was from Cayman Chemical (Ann Arbor,
MI), the antibody against COX-2 was obtained from Enzo Life
Sciences (Loerrach, Germany).
Materials used: DMEM/High Glucose (4.5 g/l) medium, penicil-
lin, streptomycin, trypsin/EDTA solution, PAA Laboratories (Linz,
Austria); l-Carrageenan type IV isolated from Gigartina aciculaire
and Gigartina pistillata and indomethacin were purchased from
Sigma–Aldrich (Milan, Italy); PGH2, Larodan (Malmo¨, Sweden);
11b-PGE2, PGB1,MK-886 (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-
isopropylindol-2-yl]-2,2-dimethylpropanoic acid), 6-keto PGF1a,
Cayman Chemical (AnnArbor,MI); UltimaGoldTMXR, Perkin Elmer
(Boston, MA); [3H]-PGE2 was from PerkinElmer Life Sciences
(Milan, Italy) and PGE2 antibody from Sigma–Aldrich (Milan, Italy).
All other chemicals were obtained from Sigma–Aldrich (Deisen-
hofen, Germany) unless stated otherwise.
2.2. Cells and cell viability assay
A549 cells were cultured in DMEM/High Glucose (4.5 g/l)
medium supplementedwith heat-inactivated fetal calf serum (FCS,10%, v/v), penicillin (100 U/ml), and streptomycin (100mg/ml) at
37 8C in a 5% CO2 incubator. After 3 days, conﬂuent cells were
detached using 1 trypsin/EDTA solution and reseeded at 2  106
cells in 20 ml medium in 175 cm2 ﬂasks.
Blood cells were freshly isolated from leukocyte concentrates
obtained at the Blood Center of the University Hospital Tuebingen
(Germany) as described [14]. In brief, venous bloodwas taken from
healthy adult donors that did not take anymedication for at least 7
days, and leukocyte concentrates were prepared by centrifugation
(4000  g, 20 min, 20 8C). Cells were immediately isolated by
dextran sedimentation and centrifugation on Nycoprep cushions
(PAA Laboratories, Linz, Austria). Platelet-rich-plasma was
obtained from the supernatants, mixed with phosphate-buffered
saline (PBS) pH 5.9 (3:2, v/v), centrifuged (2100  g, 15 min, room
temperature), and the pelleted platelets were resuspended in PBS
pH 5.9/0.9% NaCl (1:1, v/v). Washed platelets were ﬁnally
resuspended in PBS pH 7.4 and 1 mM CaCl2. Neutrophils were
immediately isolated from the pellet after centrifugation on
Nycoprep cushions, and hypotonic lysis of erythrocytes was
performed as described [14]. Cells were ﬁnally resuspended in
PBS pH 7.4 containing 1 mg/ml glucose and 1 mM CaCl2 (PGC
buffer) (purity > 96–97%). For isolation of human monocytes,
peripheral bloodmononuclear cells (PBMC) after centrifugation on
Nycoprep cushions were washed three times with cold PBS. Then,
monocytes were separated by adherence for 1 h at 37 8C to culture
ﬂasks (Greiner,Nuertingen,Germany; cell densitywas2  107 cells/
ml of RPMI 1640medium containing 2 mM L-glutamine and 50mg/
ml penicillin/streptomycin), which ﬁnally gave a purity of >85%,
deﬁned by forward- and side-light scatter properties and detection
of the CD14 surface molecule by ﬂow cytometry (BD FACS Calibur,
Rockville, MD).Monocyteswere ﬁnally resuspended in ice-cold PBS
plus 1 mg/ml glucose or in PGC buffer.
Cell viability was assessed by trypan blue staining and light
microscopy as well as by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. In brief, A549 cells (4  105,
plated into a 75 cm3 cell culture ﬂask and grown for 72 h) or
human PBMC (106 cells/ml) were incubated at 37 8C and 5% CO2.
Then, arzanol was added and the incubation was continued for
24 h before cell viability was determined. Treatment with arzanol
(10 or 30 mM) for 24 h did not signiﬁcantly reduce cell viability in
both cell cultures, excluding acute cytotoxic effects in the cellular
assays used in this study. However, for A549 cells, incubation with
50 mM arzanol led to an increase in the ratio of dead cells to total
number of cells (80% dead cells), whereas for the PBMC population
no signiﬁcant reduction of cell viability was evident at 50 mM
arzanol (not shown).
2.3. Animals
Male adult Wistar Han rats (200–220 g, Harlan, Milan, Italy)
were housed in a controlled environment and provided with
standard rodent chow and water. Animal care complied with
Italian regulations on protection of animals used for experimental
and other scientiﬁc purpose (Ministerial Decree 116192) as well as
with the European Economic Community regulations (Ofﬁcial
Journal of E.C. L 358/1 12/18/1986).
2.4. DPPH assay
The radical scavenger capability was assessed bymeasuring the
reduction of the stable free radical 2,2-diphenyl-1-picrylhydrazyl
(DPPH). Brieﬂy, an ethanol solution of a sample at various
concentrations (100 ml) was mixed with an acetate-buffered (pH
5–6.5) DPPH solution (ﬁnal concentration 50 mM). After incuba-
tion for 30 min in the dark the absorbance of the mixture was
measured at 520 nm.
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homogenates and 40 000  g supernatants, and semi-puriﬁcation of
5-LO
E. coli MV1190 was transformed with pT3-5-LO plasmid, and
recombinant 5-LO protein was expressed at 27 8C as described
[15]. Cells were lysed in 50 mM triethanolamine/HCl pH 8.0, 5 mM
EDTA, soybean trypsin inhibitor (60 mg/ml), 1 mM phenylmetha-
nesulfonyl ﬂuoride, and lysozyme (500mg/ml), homogenized by
sonication (3  15 s), and centrifuged at 40,000  g for 20 min at
4 8C. The 40,000  g supernatant (S40) was applied to an ATP-
agarose column to partially purify 5-LO as described previously
[15]. S40 or semi-puriﬁed 5-LO were immediately used for 5-LO
activity assays.
2.6. Determination of 5-LO product formation in cell-free systems
Aliquots of S40 or semi-puriﬁed 5-LOwere dilutedwith ice-cold
PBS containing 1 mM EDTA, and 1 mM ATP was added. Samples
were pre-incubated with the test compounds as indicated. After
10 min at 4 8C, samples were pre-warmed for 30 s at 37 8C, and
2 mM CaCl2 plus 20 mM AA was added to start 5-LO product
formation. The reaction was stopped after 10 min at 37 8C by
addition of 1 ml ice-cold methanol, and the formed metabolites
were analyzed by RP-HPLC as described [16]. 5-LO products
include the all-trans isomers of LTB4 and 5(S)-hydro(pero)xy-6-
trans-8,11,14-cis-eicosatetraenoic acid.
2.7. Determination of 5-LO product formation in intact cells
Freshly isolated neutrophils (1  107/ml PGC buffer) were pre-
incubated with the test compounds for 15 min at 37 8C and 5-LO
product formation was started by addition of 2.5 mM ionophore
A23187 plus 20 mM AA. After 10 min at 37 8C, the reaction was
stopped with 1 ml of methanol and 30 ml of 1 N HCl, and then,
200 ng PGB1 and 500 ml PBS were added. Formed 5-LOmetabolites
were extracted and analyzed by HPLC as described [16]. 5-LO
products include LTB4 and its all-trans isomers, and 5(S)-
hydro(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid. Cystei-
nyl-LTs C4, D4, and E4 were not detected, and oxidation products
of LTB4 were not determined.
For stimulation with LPS/fMLP, freshly isolated neutrophils
(2  107/ml PGC buffer) were incubated with LPS (1 mg/ml). After
10 min, adenosine deaminase (Ada, 0.3 units/ml, in order to
eliminate inhibitory extracellular adenosine) and the test
compounds were added. After another 20 min, the reaction
was initiated by 1 mM fMLP. After 5 min samples were placed on
ice for 2 min, centrifuged (600  g, 10 min), and LTB4 was
determined in the supernatant using a LTB4 High Sensitivity EIA
Kit (Assay Designs, Ann Arbor, MI) according to the manufac-
turer’s protocol.
2.8. Determination of COX-1 activity in platelet homogenates and
COX-2 activity in monocyte homogenates
Platelet homogenates (containing COX-1) were prepared by
sonication (3  5 s at 4 8C) of freshly isolated platelets (108/ml PBS
containing 1 mM EDTA). Monocytes were stimulated with LPS
(10 mg/ml) for 20 h to induce COX-2 expression and cell
homogenates were prepared by sonication (3  5 s at 4 8C;
4  106/ml PBS containing 1 mM EDTA). After addition of 5 mM
glutathione and 5mM haemoglobin, homogenates were pre-
incubated with the test compounds for 4 min at room temperature
and pre-warmed 1 min at 37 8C. COX reactions were started by
addition of 5mM AA, and after 5 min at 37 8C, 1 ml ice-cold
methanol was added. The formed product 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT) was extracted and
analyzed by HPLC as described [17].
2.9. Determination of COX-1 product formation in washed platelets
Freshly isolated platelets (108/ml PBS containing 1 mM CaCl2)
were pre-incubated with the indicated agents for 10 min at room
temperature and pre-warmed for 1 min at 37 8C. After addition of
5mM AA and further incubation for 5 min at 37 8C, TXB2 formed
was quantiﬁed using a TXB2 High Sensitivity EIA Kit (Assay
Designs, Ann Arbor, MI), and 12-HHT was extracted and analyzed
by HPLC as described [17].
2.10. Determination of 6-keto PGF1a formation in intact A549 cells
The formation of 6-keto PGF1a was determined in A549 cells
according to [18]. A549 cells (2  106 cells) were incubated for 16 h
at 37 8C and 5% CO2, the medium was changed, and the cells were
stimulated with IL-1b (1 ng/ml) for 48 h. After trypsination, cells
were washed with PBS twice, and 2  106 cells were resuspended
in 1 ml PBS containing CaCl2 (1 mM), pre-incubated with the
indicated compounds for 10 min at 37 8C, and 6-keto PGF1a
formation was initiated by addition of AA (1mM). After 30 min at
37 8C, the reaction was stopped by cooling on ice. Cells were
centrifuged (300  g, 5 min, 4 8C), and the amount of released 6-
keto PGF1a was assessed by the High Sensitivity EIA Kit (Assay
Designs, Ann Arbor, MI) according to the manufacturer’s protocol.
2.11. Determination of PGE2 formation in intact human monocytes
Formation of PGE2 in intact cells was determined in monocytes
according to Karlsson et al. [19]. In brief, freshly isolated
monocytes were cultured in 12-well plates (density 106/ml per
well) in RPMI medium containing 0.5% FCS and pre-treated with
LPS (1mg/ml) for 20 h. Cells were washed three times with PBS,
and new medium was added for 30 min. After the medium was
replaced again, cells were pre-incubated with the test compounds
for 15 min. PGE2 formation was initiated by addition of AA (1mM).
After 30 min, the amount of PGE2 in the supernatant wasmeasured
using a PGE2 High Sensitivity EIA Kit (Assay Designs, Ann Arbor,
MI) according to the manufacturer’s protocol.
2.12. SDS–PAGE and Western blot
Monocytes (5  106 cells) were resuspended in 50 ml PBS buffer
pH 7.2, mixed with the same volume of 2 SDS/PAGE sample
loading buffer (20 mM Tris–HCl, pH 8, 2 mM EDTA, 5% (m/v) SDS,
and 10% (v/v) b-mercaptoethanol), 20ml glycerol/0.1% bromo-
phenol blue (1:1, v/v) and boiled for 5 min at 95 8C. Proteins were
separated by SDS–PAGE. Correct loading of the gel and transfer of
proteins to the nitrocellulose membrane was conﬁrmed by
Ponceau staining. After electroblotting to nitrocellulosemembrane
(GE Healthcare, Munich, Germany) and blocking with 5% BSA for
1 h at room temperature, membranes were washed and incubated
with primary antibodies overnight at 4 8C. The membranes were
washed and incubated with a 1:1000 dilution of alkaline
phosphatase-conjugated immunoglobulin G for 1 h at room
temperature. After washing, proteins were visualized with nitro
blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate.
2.13. Determination of PGE2, 6-keto PGF1a, and TXB2 formation in
human whole blood
Peripheral blood from healthy adult volunteers, who had not
received any medication for at least 2 weeks under informed
consent, was obtained by venepuncture and collected in syringes
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0.8 ml, 6-keto PGF1a: 0.4 ml) weremixedwith CV4151 (1mM) and
with aspirin (50 mM) for determination of PGE2 and with CV4151
(1mM) for analysis of 6-keto PGF1a, respectively. For determina-
tion of TXB2, aliquots of whole blood (0.4 ml) were used without
additives. A total volume of 1 ml or 0.5 ml was adjusted with
sample buffer (10 mM potassium phosphate buffer pH 7.4, 3 mM
KCl, 140 mMNaCl, and 6 mM D-glucose). After pre-incubation with
the indicated compounds for 5 min at room temperature, the
samples were stimulated with LPS (10mg/ml) for 5 h at 37 8C.
Prostanoid formation was stopped on ice, the samples were
centrifuged (2300  g, 10 min, 4 8C) and 6-keto PGF1a and TXB2
were quantiﬁed in the supernatant using High Sensitivity EIA Kits
(Assay Designs, Ann Arbor, MI), respectively, according to the
manufacturer’s protocols. PGE2 was determined as described [18].
In brief, the supernatant was acidiﬁed with citric acid (30ml, 2 M),
and after centrifugation (2300  g, 10 min, 4 8C), solid phase
extraction and separation by RP-HPLC was performed to isolate
PGE2. The PGE2 peak (3 ml), identiﬁed by co-elution with the
authentic standard, was collected, and acetonitrile was removed
under a nitrogen stream. The pHwas adjusted to 7.2 by addition of
10 PBS buffer pH 7.2 (230 ml) before PGE2 contents were
quantiﬁed using a PGE2 High Sensitivity EIA Kit (Assay Designs,
Ann Arbor, MI) according to the manufacturer’s protocol.
2.14. Preparation of crude mPGES-1 in microsomes of A549 cells and
determination of PGE2 synthase activity
Preparation of A549 cells and determination of mPGES-1
activity was performed as described previously [18]. In brief, cells
were treated with 1 ng/ml IL-1b for 48 h at 37 8C and 5% CO2. After
sonication, the homogenate was subjected to differential centrifu-
gation at 10,000  g for 10 min and 174,000  g for 1 h at 4 8C. The
pellet (microsomal fraction) was resuspended in 1 ml homogeni-
zation buffer (0.1 M potassium phosphate buffer pH 7.4, 1 mM
phenylmethanesulfonyl ﬂuoride, 60 mg/ml soybean trypsin inhib-
itor, 1mg/ml leupeptin, 2.5 mMglutathione, and 250 mM sucrose),
and the total protein concentration was determined. Microsomal
membranes were diluted in potassium phosphate buffer (0.1 M,
pH 7.4) containing 2.5 mM glutathione. Test compounds or vehicle
were added, and after 15 min at 4 8C, the reaction (100ml total
volume) was initiated by addition of PGH2 (20 mM, ﬁnal
concentration, unless stated otherwise). After 1 min at 4 8C, the
reactionwas terminated using stop solution (100 ml; 40 mM FeCl2,
80 mM citric acid, and 10 mM of 11b-PGE2 as internal standard).
PGE2 was separated by solid phase extraction and analyzed by RP-
HPLC as described [18].
2.15. Carrageenan-induced pleurisy in rats
Arzanol (3.6 mg/kg) or indomethacin (5 mg/kg) were given i.p.
30 min before carrageenan. A group of male rats received the
vehicle (DMSO, 4%, i.p.) 30 min before carrageenan. Rats were
anaesthetized with enﬂurane 4% mixed with O2, 0.5 l/min, N2O
0.5 l/min and submitted to a skin incision at the level of the left
sixth intercostal space. The underlying muscle was dissected, and
saline (0.2 ml) or l-carrageenan type IV 1% (w/v, 0.2 ml) was
injected into the pleural cavity. The skin incision was closed with a
suture, and the animals were allowed to recover. At 4 h after the
injection of carrageenan, the animals were killed by inhalation of
CO2. The chest was carefully opened, and the pleural cavity was
rinsed with 2 ml saline solution containing heparin (5 U/ml). The
exudate andwashing solutionwere removed by aspiration, and the
total volume was measured. Any exudate that was contaminated
with blood was discarded. The amount of exudates was calculated
by subtracting the volume injected (2 ml) from the total volumerecovered. Leukocytes in the exudates were resuspended in PBS
and counted with an optical light microscope in a Burker’s
chamber after vital trypan blue staining.
The amounts of PGE2, LTB4 and 6-keto PGF1a in the supernatant
of centrifuged exudate (800  g for 10 min) were assayed by
radioimmunoassay (PGE2) and enzyme immunoassay (LTB4, 6-
keto PGF1a), respectively (Cayman Chemical, Ann Arbor, MI)
according to manufacturer’s protocol. The results are expressed as
ng per rat and represent the mean  S.E. of 10 rats.
2.16. Statistics
Data are expressed asmean  S.E. IC50 values are approximations
determined by graphical analysis (linear interpolation between the
points between 50% activity). The program Graphpad Instat
(Graphpad Software Inc., San Diego, CA) was used for statistical
comparisons. Statistical evaluation of the datawas performed by one-
way ANOVAs for independent or correlated samples followed by
Tukey HSD post hoc tests. A P value of <0.05 (*) was considered
signiﬁcant.
3. Results
3.1. Effects of arzanol on 5-LO product formation
Many plant-derived 5-LO inhibitors are lipophilic reducing
agents that act by uncoupling the redox cycle of the active-site iron
of 5-LO or by radical scavenging activity [5]. In agreement with the
result from previous studies [12], we could conﬁrm the anti-
oxidant properties of arzanol. Thus, arzanol caused a concentra-
tion-dependent reduction of DPPH with similar efﬁciency as well-
recognized antioxidants such as L-cysteine or ascorbic acid (IC50
approx. 20 mM, Fig. 1B). Based on the anti-oxidant effect and the
lipophilic structure, we hypothesized that arzanol could interfere
with 5-LO, a redox-regulated dioxygenase. As shown in Fig. 1C,
arzanol potently suppressed the activity of semi-puriﬁed 5-LO in a
cell-free assay with an IC50 = 3.1mM. Wash-out experiments
demonstrated that this effect was reversible, as incubation of 5-
LO with 10 mM arzanol and subsequent dilution to 1 mM (ﬁnal
concentration) abolished 5-LO inhibition (Fig. 1D).
Next, we evaluated the effects of arzanol on 5-LO activity in
intact human neutrophils. A concentration-dependent inhibition
of 5-LO product synthesis by arzanol was evident for cells
stimulated with ionophore A23187 plus exogenous AA (20 mM)
as well as for cells primed with LPS (1mg/ml, 30 min) and then
stimulated with 100 nM fMLP (IC50 = 2.9 and 8.1 mM, respectively,
Fig. 1E). An interference with AA supply, e.g., by inhibition of cPLA2
can be excluded, because for A23187-activated neutrophils
exogenous AA was provided, and thus endogenous substrate
supply was circumvented. Also, arzanol up to 10 mM failed to
inhibit isolated recombinant human cPLA2whereas the pyrrolidine
cPLA2a inhibitor (5mM)was active (not shown). The 5-LO inhibitor
BWA4C (0.3 mM), used as reference compound, blocked 5-LO
activity in all assays as expected (inhibition >90%, not shown).
Together, arzanol is a direct inhibitor of 5-LOwith efﬁciency also in
intact cells.
3.2. Effects of arzanol on prostanoid formation
Prostanoids derived from the COX pathway are major
inﬂammatory mediators formed by redox-sensitive dioxygenases,
and thus we also evaluated the effects of arzanol on COX activity.
As a robust test system for COX-1, we used human platelets pre-
incubated with test compounds for 10 min and we measured the
formation of 12-HHT and TXB2 after addition of the COX substrate
AA (5mM). The formation of both 12-HHT and TXB2 was
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Fig. 2. Effects of arzanol on COX-1 activity. (A) COX-1 activity in human platelets. Platelets (108/ml PBS containing 1 mM CaCl2) were pre-incubated with the indicated
concentrations of arzanol or vehicle (veh, DMSO) for 5 min prior to stimulation with AA (5 mM). After another 5 min at 37 8C, the formation of 12-HHT and TXB2 was assessed
by HPLC and by ELISA, respectively. TXB2 formed in the absence of test compounds averaged at 130 ng/ml (100%, control). The formation of 12-HHT was determined by RP-
HPLC as described. 12-HHT formed in the absence of test compounds averaged at 56 ng/ml (100%, control). (B) COX-1 activity in platelet homogenates. Platelet homogenates
were supplemented with 5 mM glutathione and 5 mM haemoglobin and pre-incubated with the test compounds or vehicle (veh, DMSO) for 4 min at RT and 1 min at 37 8C.
Then, 5mMAAwas added, and after 5 min at 37 8C the amounts of 12-HHT formed were analyzed by HPLC. Data are given as mean + S.E., n = 4, **p < 0.01 or ***p < 0.001 vs.
vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc tests. Indo, indomethacin (10 mM).
J. Bauer et al. / Biochemical Pharmacology 81 (2011) 259–26864concentration-dependently inhibited by arzanol with IC50 = 2.3
and 2.9 mM, respectively (Fig. 2A). Platelets also express the
platelet-type 12-LO that converts AA to 12-H(P)ETE and we also
observed a suppression of 12-HETE synthesis by arzanol at higher
concentrations (IC50 approx. 20 mM, data not shown). Note that
interference of arzanol with signalling pathways and release of AA
as substrate can again be excluded since AA was supplied
exogenously. In fact, arzanol inhibited COX-1 activity also in
cell-free assays using lysates of human platelets as source of COX-1
enzyme (IC50 = 17.5mM, Fig. 2B).
For analysis of modulation of COX-2 activity, human lung
epithelial A549 cells were treated with IL-1b to induce COX-2 and
to form the stable PGI2 degradation product 6-keto PGF1a (as
biomarker for PGI2 formation) from exogenous AA (1mM) [18]. A
contribution of COX-1 can be excluded in these cells because COX-
1 is detectable neither at the protein nor at its corresponding
mRNA level [12,20]. Arzanol moderately inhibited 6-keto PGF1a
formation, with an apparent IC50  30 mM (Fig. 3A). Higher
concentrations of arzanol were not tested because at 50mM,
but not at 30 mM, arzanol signiﬁcantly impaired cell viability (by
80% within 24 h, assessed by MTT assay, not shown). Along these
lines, arzanol up to 30 mM failed to substantially inhibit COX-2 in a
cell-free assay where human monocytes were used as enzyme
source; indomethacin (10mM) and the COX-2 selective celecoxib
(5 mM) clearly blocked COX-2 activity (Fig. 3B).
In addition, we investigated the effects of arzanol on cellular
COX-2-derived PGE2 formation in intact human monocytes
derived from peripheral blood that were stimulated with LPS for
24 h and subsequently PGE2 was assessed by ELISA [19].
Monocyte-based PGE2 analysis by ELISA is convenient and, in
contrast to A549 cells, does not require preceding separation of
prostanoids prior to ELISA or laborious pre-labelling with [3H]AA
[3]. Thus, IL-1b-treated A549 cells might produce substantial
amounts of other prostanoids (e.g., 6-keto PGF1a) and related
products that seemingly interfere with commercially available
PGE2 ELISA detection systems, see also [18]. The COX inhibitor
indomethacin and the mPGES-1 inhibitor MD52 were used as
controls. Arzanol signiﬁcantly inhibited PGE2 formation already at
3 mM and the IC50 was determined at 9mM (Fig. 3C). This
inhibitory effect was not related to an accompanied interference
with the expression of COX-2 or mPGES-1 by arzanol (Fig. 3D).
Along these lines, arzanol inhibited PGE2 formation in humanwhole blood stimulated with LPS for 5 h, starting at 3mM, and at
30 mM arzanol PGE2 synthesis was repressed by about 50%
(Fig. 4A). In parallel, the accompanied COX-2-mediated biosynthe-
sis of TXB2 (Fig. 4B) and the COX-2-derived 6-keto PGF1a formation
(Fig. 4C) were not signiﬁcantly inhibited by arzanol. It is worth
notice that the selective mPGES-1 inhibitor MD52 showed a
comparable inhibitory proﬁle, clearly reducing PGE2 synthesis in
LPS-treated monocytes and whole blood, but hardly affecting 6-
keto PGF1a in the respective assays. In contrast, indomethacin
blocked the formation of the analyzed prostanoids in all assays, as
expected. Taken together, arzanol obviously inhibits COX-1
activity but is a poor inhibitor of COX-2 derived prostanoids,
except for PGE2 which is clearly suppressed.
3.3. Effects of arzanol on mPGES-1
The suppression of PGE2 formation by arzanol without
concomitant inhibition of other COX-2-derived prostanoids led
us to hypothesize that arzanol could interfere with mPGES-1.
Microsomal preparations of IL-1b-stimulated A549 cells, used as
source of mPGES-1 [21], were pre-incubated with test compounds
for 15 min, and then, PGE2 formation was initiated by addition of
20 mM PGH2. The mPGES-1 inhibitor MK-886 (used as control)
blocked PGE2 formation with an IC50 of 2.1 mM (data not shown).
Arzanol concentration-dependently inhibited PGE2 formationwith
an IC50 = 0.4 mM (Fig. 5A) being superior over MK-886. Alteration
of PGH2 to lower (1mM) or higher (50 mM) concentration caused
only slight changes in the potency of arzanol (Fig. 5B), suggesting
that mPGES-1 inhibition is largely independent of the substrate
concentration.
To investigate whether arzanol inhibits PGE2 synthesis in a
reversible manner, wash-out experiments were carried out.
Arzanol failed to efﬁciently block PGE2 synthesis at 0.1 mM,
whereas PGE2 formationwas efﬁciently inhibited at 1mM(Fig. 5C).
However, 10-fold dilution of the samples containing 1mM arzanol
restored mPGES-1 activity implying a reversible mode of inhibi-
tion. It appeared possible that arzanol could directly act on PGH2
and thus inhibit non-enzymatic PGE2 formation independent of
mPGES-1. However, when the microsomal preparations of A549
cells were heat-inactivated (15 min/65 8C) the non-enzymatic
PGE2 formation was not affected by arzanol up to 10 mM (not
shown).
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Fig. 3. Effects of arzanol on COX-2 activity. (A) 6-Keto PGF1a formation as parameter of COX-2 activity. IL-1b-stimulated A549 cells (1  106/ml) were pre-incubated with
arzanol, indomethacin (Indo, 10mM) or vehicle (veh, DMSO) as indicated for 15 min at RT prior to addition of 1mMAA. After 30 min at 37 8C the amount of 6-keto PGF1awas
assessed by ELISA as described. The 100% value corresponds to an average of 1.2 ng/ml 6-keto PGF1a. (B) COX-2 activity in monocyte homogenates. Monocytes were
stimulated with LPS (10 mg/ml) for 20 h, cell homogenates were prepared, 5 mM glutathione and 5 mM haemoglobin were added, and pre-incubated with arzanol,
indomethacin (Indo, 10mM), celecoxib (Cele, 5mM) or vehicle (veh, DMSO) for 4 min at RT and 1 min at 37 8C. Then, 5mMAAwas added and 12-HHTwas analyzed by HPLC.
(C) PGE2 formation as parameter of COX-2 activity. Monocytes were pre-treated with LPS (1 mg/ml) for 20 h, cells were washed, and pre-incubated with arzanol,
indomethacin (Indo, 10mM), MD52 (2mM) or vehicle (veh, DMSO) for 15 min. PGE2 formation was initiated by addition of AA (1 mM), and after 30 min, PGE2 in the
supernatant was analyzed by ELISA. (D) Expression of COX-2 and mPGES-1. Monocytes (2  106 cells/ml RPMI plus 0.5% FCS) were incubated in the presence or absence of
10mg/ml LPS together with arzanol, dexamethasone (1 mM) or vehicle (DMSO) for 20 h at 37 8C. Cells were harvested, lysed by addition of SDS/PAGE sample loading buffer
and proteinswere separated by SDS–PAGE and analyzed for COX-2 (upper panel) andmPGES-1 (lower panel) byWB. Ponceau S staining conﬁrms equal loading of protein and
transfer of proteins to the membrane. Data are given as mean + S.E., n = 3–4, **p < 0.01 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc tests.[(Fig._4)TD$FIG]
100
140
A B C
P
G
E
2
fo
rm
at
io
n
(p
er
ce
n
ta
g
e 
o
f 
co
n
tr
o
l)
20
40
60
80
T
X
B
2 
fo
rm
at
io
n
(p
er
ce
n
ta
g
e 
o
f 
co
n
tr
o
l)
20
40
60
80
100
120
6-
ke
to
 P
G
F
1 α
 
fo
rm
at
io
n
(p
er
ce
n
ta
g
e 
o
f 
co
n
tr
o
l)
20
40
60
80
100
**
***
***
**
***
***
arzanol [µM]
ve
h 1 3 10  3
0
In
do
M
D5
2
0 0 0
Fig. 4. Effects of arzanol on prostanoid formation in human whole blood. (A) PGE2 formation. Heparinized human blood, treated with 1 mM thromboxane synthase inhibitor
and 50mMaspirin, was pre-incubatedwith arzanol, indomethacin (Indo, 50 mM),MD52 (6mM) or vehicle (veh, DMSO) for 5 min at RT, and then, PGE2 formationwas induced
by addition of 10mg/ml LPS. After 5 h at 37 8C, PGE2 was extracted from plasma and analyzed as described. The 100% value corresponds to an average of 1.9 ng/ml PGE2, and
0.42 ng/ml PGE2 were detected in unstimulated blood. (B) TXB2 formation. Heparinized blood was pre-incubated with arzanol, indomethacin (Indo, 50 mM) or vehicle (veh,
DMSO, w/o) for 5 min, then 10 mg/ml LPS were added and TXB2 was analyzed after 5 h at 37 8C in the plasma by ELISA. The 100% value corresponds to an average of 58 ng/ml
TXB2. (C) 6-Keto PGF1a formation. Heparinized human blood, treated with 1mM thromboxane synthase inhibitor, was pre-incubated with arzanol, indomethacin (Indo,
50mM), MD52 (6mM) or vehicle (veh, DMSO) for 5 min at RT, prior to addition of 10mg/ml LPS. After 5 min at 37 8C, 6-keto PGF1awas directly analyzed in plasma by ELISA.
The 100% value corresponds to an average of 14.5 ng/ml 6-keto PGF1a, and 2.3 ng/ml 6-keto PGF1awere detected in unstimulated blood. Data are given as mean  S.E., n = 3,
**p < 0.01 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc tests.
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Fig. 5. Effects of arzanol on the activity of mPGES-1. (A) Concentration–response curve. Microsomal preparations of IL-1b-stimulated A549 cells were pre-incubated with
arzanol or vehicle (veh, DMSO) for 15 min at 4 8C, and the reaction was started with 20mM PGH2. After 1 min at 4 8C, the reaction was terminated using a stop solution
containing FeCl2 and 11b-PGE2 (1 nmol) as internal standard. The 100% value corresponds to an average of 0.8 nmol PGE2. (B) The potency of arzanol for mPGES-1 inhibition
was compared at 1, 20, and 50mM PGH2 as substrate. The amount of PGE2 was quantiﬁed for 1 mM PGH2 by use of a PGE2 High Sensitivity EIA Kit according to the
manufacturer’s protocol; for 20 and 50mM PGH2, the PGE2 was quantiﬁed by HPLC. The 100% values correspond to an average of 70 ng/ml (ELISA), or 1 and 5 nmol (HPLC)
PGE2 for 1, 20, and 50mMPGH2, respectively. (C) Reversibility ofmPGES-1 inhibition by arzanol. Microsomal preparations of IL-1b-stimulated A549 cells were pre-incubated
with 1mM inhibitor for 15 min at 4 8C. An aliquot was diluted 10-fold to obtain an inhibitor concentration of 0.1 mM. For comparison, microsomal preparations were pre-
incubated for 15 minwith vehicle (veh, DMSO, w/o) or 0.1 mMarzanol, and then, 20mMPGH2was added (no dilution). All samples were incubated for 1 min on ice, and PGE2
formation was analyzed as described by HPLC. Data are given as mean + S.E., n = 3–4, *p < 0.05 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc
tests.
Table 1
Effect of arzanol on carrageenan-induced pleurisy in rats.
Treatment Exudate volume (ml) Inﬂammatory cells 106 PGE2 (ng/rat) LTB4 (ng/rat) 6-Keto PGF1a (ng/rat)
Vehicle 0.41 0.019 46.56.0 4.26 0.67 1.22 0.26 10.721.43
Arzanol (3.6mg/kg) 0.17 0.05*** (59%) 24.05.9* (48%) 2.27 0.35* (47%) 0.84 0.21 (31%) 7.79 0.72 (27%)
Indomethacin (5mg/kg) 0.10 0.03*** (76%) 16.282.30*** (65%) 0.21 0.024*** (95%) 1.06 0.20 (13%) 0.64 0.09*** (94%)
Thirty minutes before intrapleural injection of carrageenan, rats (n=10 per group) were treated i.p. with 3.6mg/kg arzanol, indomethacin (5mg/kg) or vehicle (DMSO 4%).
Exudate volume, eicosanoids, and inﬂammatory cell accumulation in the pleural cavity were assessed 4h after carrageenan injection. Data are expressed as mean SEM.
* p<0.05 vs. vehicle.
*** p<0.001 vs. vehicle.
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inhibits eicosanoid bisosynthesis in vivo
The anti-inﬂammatory effectiveness of arzanol was assessed in
vivo using carrageenan-induced pleurisy in rats. Injection of
carrageenan into the pleural cavity of rats (DMSO 4% group)
elicited an inﬂammatory response within 4 h, characterized by the
accumulation of ﬂuid that contained large numbers of inﬂamma-
tory cells (Table 1). The dose of arzanol was chosen at 3.6 mg/kg,
i.p., 30 min prior to carrageenan based on the experiences from
previous animal studies using myrtucommulone or hyperforin
with comparable efﬁciency to arzanol in vitro [22,23]. Arzanol
inhibited the inﬂammatory response as demonstrated by the
signiﬁcant attenuation of exudate formation (59%) and cell
inﬁltration (48%). Indomethacin (5 mg/kg) reduced exudate
formation and cell inﬁltration by 75% and 65%, respectively (Table
1). In comparison with the corresponding exudates from DMSO-
treated rats, exudates of arzanol-treated animals exhibited
decreased PGE2 levels (47% inhibition), whereas indomethacin
almost completely suppressed PGE2 (95%) as well as 6-keto PGF1a
(94%) levels as expected. In agreement with the moderate
inhibition of COX-2-derived 6-keto PGF1a formation in A549 cells
or human whole blood (see above), arzanol also slightly reduced
the levels of 6-keto PGF1a (27% inhibition). On the other hand,
indomethacin failed to signiﬁcantly reduce LTB4 levels which were
lowered by arzanol (31% inhibition, seemingly due to direct
inhibition of 5-LO).4. Discussion
Arzanol was recently characterized as the major bioactive
constituent of H. italicum with excellent anti-oxidant properties
that inhibited theHIV-1 replication in T cells and the release of pro-
inﬂammatory cytokines from stimulated monocytes, which was
attributed to interference with the NFkB pathway [8,12]. We now
report that arzanol potently inhibits the biosynthesis of PGE2,
TXB2, and LTs which are pivotal mediators of inﬂammatory
reactions, and we identiﬁed 5-LO, COX-1, and mPGES-1 as
respective molecular targets of arzanol. Importantly, suppression
of eicosanoid formation was evident also in vivo in the rat pleurisy
model, and this was accompanied by signiﬁcant anti-inﬂammatory
efﬁcacy. In the context of further preclinical studies, the marked
inhibitory activity on LTs, COX-1-derived TXA2 and COX-2-derived
PGE2, and the minor suppression of beneﬁcial prostanoids (e.g.,
PGI2, the instable precursor of 6-keto PGF1a) qualify arzanol a
valuable anti-inﬂammatory candidate.
The role of eicosanoids in inﬂammation and allergy is well
established, and drugs that interfere with either the biosynthesis
(NSAIDs) or the action (cysteinyl LT receptor antagonists) of these
lipid mediators are commonly used to treat inﬂammatory or
allergic diseases [1,24]. Arzanol inhibits eicosanoid biosynthesis by
interfering with 5-LO, mPGES-1 and COX-1, thus supporting its
anti-inﬂammatory potential. In fact, one of the most advanced
anti-inﬂammatory drug candidates, licofelone (in phase III clinical
trials) [25] also essentially acts by blocking COX-1 and mPGES-1
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inhibitors of mPGES-1 and 5-LO like the pirinixic acid derivative
YS121 [27] or myrtucommulone [28] showed comparable effects
on cellular eicosanoid biosynthesis as arzanol and both compounds
also exhibited potent anti-inﬂammatory activities in vivo [27,23].
Moreover, arzanol blocks NFkB activation and release of pro-
inﬂammatory cytokines (i.e., IL-1b, IL-6, IL-8 and TNFa) [8] that
may potentiate its anti-inﬂammatory activity. Such multi-target
properties may confer arzanol a favourable pharmacodynamic
proﬁle with possible advantages over compounds that inhibit only
mPGES-1.
COX-1/2 and 5-LO are dioxygenaseswith iron in the AA-binding
active site cycling between reduced and oxidized states during
catalysis [29,30]. Anti-oxidants and/or radical scavengers with
sufﬁcient lipophilicity (e.g., polyphenols) are well-recognized
inhibitors of 5-LO by keeping the non-heme iron in the inactive,
reduced state or by interrupting the redox cycle [5]. Arzanol
contains a phloroglucinol core with antioxidant features and
showed antioxidant activity, protected linoleic acid against free
radical attack in assays of autoxidation and EDTA-mediated
oxidation, and inhibited TBH-induced oxidative stress in VERO
cells [12]. Also in our DPPH assay, arzanol clearly acted as radical
scavenger, and interference with the enzymatic activity of 5-LO is
therefore reasonable for arzanol, as revealed by inhibition of
semipuriﬁed 5-LO in a cell-free assay. In comparison to other well-
recognized naturally occurring polyphenolic 5-LO inhibitors,
arzanol (IC50 = 3.1mM) is equipotent to caffeic acid (IC50 = 3.7mM
[31]) and evenmore potent than nordihydroguaiaretic acid (NDGA,
IC50 = 28 mM [32]), magnolol (IC50 = 15–25mM) [33] or the
structurally related myrtucommulone (IC50 = 5mM [34]). Impor-
tantly, arzanol inhibited 5-LO product formation also in intact
neutrophils at similar concentrations as in the cell-free assay,
implying that the reduced synthesis of 5-LO products in the cell
might be related to direct interference of arzanol with the 5-LO
enzyme. This however, supposes essentially unimpeded distribu-
tion of arzanol to the intracellular space but also multiple
mechanisms in the cell-based system may contribute to suppres-
sion of 5-LO product synthesis. Since arzanol failed to inhibit cPLA2
activity which is thought to be the major enzyme in neutrophils
providing AA as substrate for 5-LO [35], suppression of 5-LO
product synthesis at this level can be excluded. Furthermore, the
efﬁciency of arzanol was comparable under conditions where
substrate was provided from endogenous sources (stimulation
with A23187 or LPS/fMLP) or, alternatively, supplemented
exogenously (i.e., 20 mM AA).
NSAIDs essentially act by inhibiting COX-1 and COX-2 with
different preferences for each individual drug [36,37]. Arzanol
inhibited COX-1-mediated 12-HHT and TXB2 synthesis in platelets
treatedwith AA equallywell whereas 12-LO product synthesis was
less affected. Again, interference of arzanol with substrate supply
can be excluded under these conditions and a direct effect of
arzanol on COX-1 is assumed, supported by the inhibition of COX-1
activity in the cell-free assay, where other cellular parameters are
not operative. Remarkably, arzanol (IC50 = 2.3–2.9mM) is equipo-
tent or even more potent than ibuprofen (IC50 = 3–70 mM [38,39])
or aspirin (IC50 = 3.2mM [38]) in platelets, which are frequently
used as COX inhibitors in the clinics [40].
In contrast to the consistent inhibition of COX-1 product
formation, the suppression of COX-2-derived prostanoid genera-
tion by arzanol was heterogeneous. Arzanol blocked cellular PGE2
synthesis and our data suggest that the selective suppression of
PGE2 is primarily due to interference with mPGES-1 but not with
COX-2. Thus, arzanol hardly inhibited COX-2 activity in a cell-free
assay (IC50  30 mM) under conditions where COX-1 was potently
blocked. In IL-1b-treated A549 cells expressing solely COX-2,
arzanol (30 mM) caused only modest inhibition of 6-keto PGF1aformation. However, arzanol (3mM) efﬁciently inhibited PGE2
synthesis in LPS-stimulated monocytes, where also COX-2 is the
predominant isoform under the respective experimental condi-
tions [41]. Analysis of COX-2 and mPGES-1 protein in monocytes
ruled out any genomic effects of arzanol on the expression level of
these inﬂammatory end-points.
Divergent effects of arzanol on COX-2-derived prostanoid
formation were also apparent when the compound was analyzed
in the human whole blood assay. Neither TXB2 synthesis nor
formation of 6-keto PGF1awere signiﬁcantly reduced up to 30 mM
arzanol in this assay, whereas under the same conditions arzanol
suppressed PGE2 synthesis at relatively low concentrations (3mM)
but reached a plateau at higher concentrations (30 mM) where
about 50% PGE2 still remained. Also the potent mPGES-1 inhibitor
MD52 suppressed PGE2 formation only by 50%, and failed to block
TXB2 and 6-keto-PGF1a, supporting mPGES-1 as the respective
target of arzanol. Presumably, other PGES isoforms unaffected by
MD52 or arzanol contribute to the basal PGE2 generation in whole
blood. On the other hand, the PGE2 ELISA detection systems may
recognize related (non-prostanoid) cross-reactive substances,
supported by the incomplete suppression of PGE2 formation by
indomethacin in whole blood while TXB2 and 6-keto-PGF1a
synthesis is effectively inhibited.
Arzanol reduced the inﬂammatory reaction in an in vivo model
of acute inﬂammation, the carrageenan-induced rat pleurisy, with
activity almost comparable to that of indomethacin. PGE2 plays a
central role in the early phase of carrageenan-induced pleurisy
[42], and COX-inhibitors prevent the inﬂammatory response.
Accordingly, lowering PGE2 by inhibition of mPGES-1 may
contribute to the anti-inﬂammatory properties of arzanol. As
observed in the whole blood assay, arzanol was less potent than
indomethacin in the reduction of PGE2 levels, but still efﬁciently
suppressed exudate formation and inﬁltration of inﬂammatory
cells. In contrast to indomethacin, arzanol also reduced the levels
of LTB4 in the pleural exudates. Since 5-LO-derived metabolites
cooperate with PGE2 in the induction of pleurisy [43], inhibition of
5-LO may contribute to the anti-inﬂammatory effect of arzanol.
Indeed, synergistic anti-inﬂammatory effects of so-called dual 5-
LO/COX have been observed [25,44]. The concomitant blockade of
LTB4 formation is seemingly also responsible for the lack of gastric
toxicity (the most troublesome side effect of NSAIDs) observed
with 5-LO/COX dual inhibitors [44]. Future studies using animal
models of gastric toxicity will reveal whether arzanol might exert
its anti-inﬂammatory activity without gastric side effects. Taken
together, our data show that arzanol potently inhibits the
biosynthesis of pro-inﬂammatory lipid mediators like PGE2 in
vitro and in vivo, providing a mechanistic rationale for the anti-
inﬂammatory activity ofH. italicum, and a rationale for further pre-
clinical evaluation of this novel anti-inﬂammatory lead.
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